Selection of a Protective T Cell-based HIV-1/FIV Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

270 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2028-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to develop a vaccine against Human immunodeficiency virus (HIV), a disease that causes AIDS in people,. The investigator will be looking at viruses similar to HIV in animals. Since these viruses are very similar to HIV, the blood from humans who have been exposed to HIV will be tested to see if the immune system will recognize the HIV and prevent infection.

HIV targets the immune system by attacking certain T cells called CD4+ T cells. There are parts on the AIDS viruses that help the virus infect these cells and other parts that help the immune system prevent viral infection by activating protective T-cells that fight HIV. Different T-cell populations are very important in most vaccines as they act as "effectors" that work as part of the immune system to recognize and fight off HIV infection. When effector T cells are activated by appropriate "protective" part(s) of the virus they either block HIV from reproducing or kill HIV infected cells. By finding these common protective parts of each of these human and animal AIDS viruses, the investigator hopes to make a vaccine that helps the immune system prevent HIV infection by avoiding parts that attack CD4+ T cells and may worsen HIV infection and selecting for parts that stimulate effector T cells that fight HIV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00058734

HIV Infections

COMPLETED PHASE1

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

NCT02388594

Human Immunodeficiency Virus (HIV)

COMPLETED PHASE1

Development of a New HIV Vaccine

NCT00051922

HIV Infections

COMPLETED PHASE1

Screening HIV-Infected Patients for Vaccine Studies

NCT00051519

HIV Infection

COMPLETED

Analysis of Immune Responses to HIV Vaccines

NCT00068978

Acquired Immunodeficiency Syndrome HIV Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As a participant in this study a blood drawn will performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV positive subjects

This group will provide a blood sample.

HIV positive subjects

Intervention Type OTHER

This group will provide a blood sample.

Non-infected control subjects

This group consist of de-identified blood samples from a commercial source.

Non-infected control subjects

Intervention Type OTHER

This group will be de-identified blood samples from a commercial source.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HIV positive subjects

This group will provide a blood sample.

Intervention Type OTHER

Non-infected control subjects

This group will be de-identified blood samples from a commercial source.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects between 18 and 65 years old who are HIV positive

Exclusion Criteria

* Persons with other immune diseases that would result in autoimmunity or aberrant immune responses (such as subjects who have undergone chemotherapy within the past year).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No